Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) ACTIVASE rt-PA alteplase 50mg powder for solution for injection (Canada)
Section 19A approved medicine
(Approval lapsed) ACTIVASE rt-PA alteplase 50mg powder for solution for injection (Canada)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN: 20605457430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
ACTILYSE alteplase (rch) 50 mg powder for injection vial with diluent vial AUST R: 17905
Indication(s)
ACTIVASE rt-PA (alteplase for injection) is indicated for:
- The lysis of suspected occlusive coronary artery thrombi associated with evolving transmural myocardial infarction. Treatment should be initiated as soon as possible after the onset of acute myocardial symptoms.
- The management of acute ischemic stroke (AIS) in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage.
Images
